Eligibility Inflammation NCT01611688

active ra, characterised by a das28 (crp)(disease activity score based on 28 joints and crp) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening

concomitant treatment with mtx (7.5 - 25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing

subjects with chronic inflammatory autoimmune disease other than ra

history of or current inflammatory joint disease other than ra such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or lyme disease

any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to randomisation

clinically significant cardiac or cardiovascular disease

past or current malignancy

latent or active tuberculosis (tb) as documented by: a positive quantiferon® test (test can be performed up to 2 months prior to dosing). one retest is allowed in case of inconclusive results.- a history of active tb within the last 3 years even, if treated effectively. - a history of active tb more than 3 years ago, if there is no documentation that the prior anti-tb treatment was appropriate in duration and type